Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jonathan Rajkumar"'
Autor:
Wolfram Samlowski, Robert Nicholas, Tayla Poretta, Andriy Moshyk, Jonathan Rajkumar, Anthony Salvatore, Esmond Nwokeji
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/22bbe2becba34e69a5fca006b0e63577
Autor:
Wolfram Samlowski, Phillip Chan, Anna Pavlick, Justin Moser, Nicholas Robert, Tayla Poreta, Andriy Moshyk, Leon Sakkal, Jennell Palaia, Nicole Niehoff, Jonathan Rajkumar, Asim Amin
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::575c6bee0eacc7864e00cc18aa7bb814
https://doi.org/10.1136/jitc-2022-sitc2022.0430
https://doi.org/10.1136/jitc-2022-sitc2022.0430
Autor:
Paula D. Ryan, Yu-Jing Huang, Kristin M Sheffield, Gebra Cuyun Carter, Jonathan Rajkumar, Lavanya Sudharshan, Gregory L Price, Claudia Morato Guimaraes, Emily Nash Smyth, Sarah Rybowski
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:HSR21-051
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaaec05c52b133dd6b916c6841e163bd
https://doi.org/10.6004/jnccn.2020.7739
https://doi.org/10.6004/jnccn.2020.7739
Autor:
Gregory L. Price, Lavanya Sudharshan, Paula Ryan, Jonathan Rajkumar, Kristin M. Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Gebra Cuyun Carter, Wambui Grace Gathirua-Mwangi, Yu-Jing Huang
To examine the real-world incidence and management of select adverse events (AEs) among female patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC), receiving a cycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f302f97c69be8f8625a8f49aa59bbbc
Autor:
Wolfram E. Samlowski, Robert Nicholas, Anthony Salvatore, Jonathan Rajkumar, Tayla Poretta, Esmond D. Nwokeji, Andriy Moshyk, Brian Stwalley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Nivolumab is approved in the US and EU for the adjuvant treatment of resected stage III-IV melanoma based on results from the CheckMate-238 clinical trial.1,2 However, the trial did not enroll any patients with Stage IIIA disease per the A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db70664c78316b34b6f69659a30d1b39
https://doi.org/10.1136/jitc-2020-sitc2020.0220
https://doi.org/10.1136/jitc-2020-sitc2020.0220